Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388967 · ClinicalTrials.gov registry record
Pancreatic Cancer Detection Consortium
A clinical trial of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 11
- Study locations
NCT06388967: Recruiting study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
NCT06388967 is a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 2,000 participants, above the 386-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (418% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388967, a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Primary Outcome
True positive rate: the probability of a positive test result, conditioned on the individual truly being positive
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PANcreatic cancer Exosome Early detectiON (PANXEON)
Study Locations (11)
Arizona
- Translational Genomics Research Institute - Phoenix
- Honorhealth - Scottsdale
California
- City of Hope Medical Center - Monrovia
- Hoag Center - Newport Beach
Other
- Nagoya University - Nagoya
- Asan Medical Center - Seoul
Illinois
- OSF HealthCare - Peoria
Louisiana
- Ochsner Medical Center - Jefferson
New Jersey
- Atlantic Health System - Morristown
South Carolina
- Piedmont Medical Center - Rock Hill
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-06-18 |
What NCT06388967 shows while recruiting
NCT06388967 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 386-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (418% higher).
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PANcreatic cancer Exosome Early detectiON (PANXEON) is the first listed.
NCT06388967 lists 11 locations in 8 states (Arizona, California, Other).
Frequently Asked Questions
What is clinical trial NCT06388967 about?
NCT06388967 is a clinical study titled "Pancreatic Cancer Detection Consortium". This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
What is the current status of trial NCT06388967?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-03-15. Estimated completion is 2026-06-18.
What conditions does trial NCT06388967 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Carcinoma.
What interventions are being tested in trial NCT06388967?
The interventions under investigation include: PANcreatic cancer Exosome Early detectiON (PANXEON) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06388967?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388967 being conducted?
This trial has 11 study locations across Arizona, California, Illinois, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06388967's enrollment target sits among peer trials
2,000 10th of 278 higher than 269 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI